Figure 7.

CaMKIV upregulates the expression of CREM and its binding to the –180 site of the IL-2 promoter in SLE T cells. (A) Normal T cells were transfected with a CaMKIV expression construct for the indicated time, and the lysates were blotted with an anti-CaMKIV or an anti-hnRNP (control) antibody. (B) SLE T cells were transfected with control plasmid or a plasmid overexpressing CaMKIV and then were treated with PMA and ionomycin. Four hours later, nuclear proteins were purified, and Western blotting was conducted by sequential use of antibodies as indicated. An antibody against hnRNP was used as control. (C) SLE T cells were transfected with control plasmid or a plasmid expressing wild-type CaMKIV and then were treated with PMA and ionomycin. At the indicated time points, cells were harvested, and EMSA was conducted using the oligonucleotide encoding the –180 site of the IL-2 promoter. (D) Cumulative time-curve results of the effect of CaMKIV overexpression in normal and SLE T cells. The y axis represents the ratio of the intensity of the –180/protein complex in the CaMKIV-transfected cells to that in the cells transfected with control plasmid. Normal and SLE T cells were subjected to the experimental protocol detailed in C. Filled symbols, SLE T cells; open symbols, normal T cells. *P < 0.05.